{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/hmg-peptide\/","title":{"rendered":"HMG (Human Menopausal Gonadotropin \/ Menotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HMG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Gonadotropina menop\u00e1usica humana, tambi\u00e9n conocida como <strong>menotropina<\/strong>; CAS 61489-71-2) es una preparaci\u00f3n de glicoprote\u00edna hormonal derivada de orina que contiene igual actividad biol\u00f3gica de LH y FSH (75 IU de LH + 75 IU de FSH por vial, la proporci\u00f3n est\u00e1ndar 1:1). Purificada a partir de la orina de mujeres posmenop\u00e1usicas \u2014cuya producci\u00f3n de gonadotropinas pituitarias est\u00e1 naturalmente elevada por la ausencia de inhibici\u00f3n por retroalimentaci\u00f3n negativa\u2014, la hMG es el <strong>agonista dual LHCGR + FSHR<\/strong> in endocrine pharmacology and the reference tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied pharmaceutical-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. <em>For clinical studies use only.<\/em> Distinto de las preparaciones cl\u00ednicas de menotropina (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Clase de compuesto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparado de glicoprote\u00edna hormonal \u2014 mezcla fija 1:1 de actividad biol\u00f3gica de LH y FSH; agonista dual del receptor de LH\/CG (LHCGR) + receptor de FSH (FSHR); preparado de hormona pept\u00eddica<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nombre qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotropina menop\u00e1usica humana (Menotropina; preparado extra\u00eddo de orina; sin\u00f3nimos: hMG, urofollitropina con LH, gonadotropina menop\u00e1usica)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (preparado mixto de menotropina \/ hMG)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Componentes activos<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (hormona luteinizante, heterod\u00edmero de ~30 kDa; \u03b1 92 aa + \u03b2 121 aa, glicosilada) \u2014 75 UI por vial; <strong>FSH<\/strong> (hormona fol\u00edculo-estimulante, heterod\u00edmero de ~30 kDa; \u03b1 92 aa + \u03b2 111 aa, glicosilada) \u2014 75 UI por vial. La subunidad \u03b1 es com\u00fan entre LH, FSH, HCG y TSH; las subunidades \u03b2 confieren especificidad al receptor. Ambas gonadotropinas est\u00e1n extensamente N- y O-glicosiladas.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Proporci\u00f3n de actividad biol\u00f3gica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Actividad LH:FSH = 1:1 (la proporci\u00f3n est\u00e1ndar de hMG desde la estandarizaci\u00f3n de potencia a finales de los 90; ambas actividades medidas mediante bioensayo de la OMS contra est\u00e1ndares de referencia internacionales)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG Co-Purification (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Una caracter\u00edstica de los preparados de hMG derivados de orina: an\u00e1lisis de composici\u00f3n publicados informan que aproximadamente <strong>el 95% de la actividad biol\u00f3gica mediada por el receptor de LH in vivo es atribuible a trazas de HCG co-purificadas de orina postmenop\u00e1usica<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH&#8217;s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Users should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agonismo dual de GPCR. <strong>LHCGR<\/strong> (Acoplado a Gs, c\u00e9lulas de Leydig\/t\u00e9cas\/granulosas\/cuerpo l\u00fateo) \u2192 cascada cAMP-PKA-StAR-CYP17A1 \u2192 bios\u00edntesis de andr\u00f3genos. <strong>FSHR<\/strong> (Acoplado a Gs, c\u00e9lulas de Sertoli en hombres\/c\u00e9lulas granulosas en mujeres) \u2192 cascada cAMP-PKA-CYP19A1\/aromatasa \u2192 soporte de la espermatog\u00e9nesis (hombre) o conversi\u00f3n de andr\u00f3genos a estr\u00f3genos + maduraci\u00f3n folicular (mujer). La doble activaci\u00f3n es lo que distingue la hMG de las preparaciones de LH pura (Luveris\/rLH) o FSH pura (Gonal-F\/Puregon\/rFSH).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparado mixto \u2014 tanto la LH como la FSH son glicoprote\u00ednas heterodim\u00e9ricas. Subunidad \u03b1 (compartida) ~92 aa, id\u00e9ntica en LH\/FSH\/HCG\/TSH. Subunidad \u03b2 de LH ~121 aa, subunidad \u03b2 de FSH ~111 aa. Secuencias completas disponibles en UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Preparado mixto de glicoprote\u00ednas extra\u00eddas de orina \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) heterod\u00edmeros en una proporci\u00f3n de bioactividad ~1:1. Sin f\u00f3rmula molecular \u00fanica debido al patr\u00f3n heterog\u00e9neo de glicosilaci\u00f3n en la preparaci\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Vida Media Plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Actividad FSH: vida media terminal ~30\u201340 h (impulsada por la sialilaci\u00f3n, similar a otras hormonas glicoproteicas). Actividad LH en hMG: nominalmente ~10\u201320 h (pero en la pr\u00e1ctica impulsada por la fracci\u00f3n de HCG copurificada con una vida media de 33\u201337 h \u2014 ver nota anterior sobre copurificaci\u00f3n de HCG).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); el bioensayo de la OMS confirma la actividad de LH y FSH en las 75 UI etiquetadas cada una. COA disponible bajo petici\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Reconstituir en agua bacteriost\u00e1tica a 1.0 mL por vial \u2192 75 UI de LH + 75 UI de FSH por mL de soluci\u00f3n de trabajo; otras diluciones seg\u00fan protocolo. El polvo se disuelve r\u00e1pidamente con un suave giro. <strong>No agitar; no vortexear<\/strong> \u2014 la mezcla de alta cizalladura disocia los heterod\u00edmeros \u03b1\/\u03b2 de los componentes de LH y FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C sin abrir para stock de trabajo a corto plazo; \u221220 \u00b0C para almacenamiento a largo plazo (estable \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Reconstituido: 2\u20138 \u00b0C, usar en ~30 d\u00edas. Proteger de la luz. <strong>No congelar el material reconstituido<\/strong> \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n disocian los heterod\u00edmeros \u03b1\/\u03b2 de LH y FSH y destruyen la bioactividad.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la HMG (Menotropina)?<\/h2>\n<p><strong>HMG<\/strong> \u2014 La Gonadotropina Menop\u00e1usica Humana, tambi\u00e9n conocida como <strong>menotropina<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause. The &#8220;menopausal&#8221; in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our pharmaceutical-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity. hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone. <strong>A studies-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH&#8217;s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal &#8220;LH activity&#8221; of LH itself being short-lived. For protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Activaci\u00f3n Dual de LHCGR + FSHR<\/h2>\n<p>El mecanismo de la hMG es la suma dual de sus dos actividades componentes, ambas bien caracterizadas en farmacolog\u00eda endocrina:<\/p>\n<ul>\n<li><strong>LH (y HCG co-purificado) \u2192 activaci\u00f3n de LHCGR<\/strong> \u2014 El componente LH (y el HCG traza que co-purifica de la orina posmenop\u00e1usica) se une al receptor LH\/CG en las c\u00e9lulas de Leydig (test\u00edculo) y c\u00e9lulas de la teca\/granulosa\/l\u00fatea (ovario). El acoplamiento Gs aumenta el cAMP, activa la PKA, regula al alza el transporte mitocondrial de colesterol mediado por StAR e induce las enzimas esteroidog\u00e9nicas CYP11A1\/CYP17A1\/3\u03b2-HSD\/17\u03b2-HSD \u2014 impulsando la bios\u00edntesis de novo de testosterona (hombre) o androstenediona (mujer).<\/li>\n<li><strong>FSH \u2192 activaci\u00f3n de FSHR<\/strong> \u2014 El componente FSH se une al receptor FSH en las c\u00e9lulas de Sertoli (test\u00edculo) y c\u00e9lulas de la granulosa mural (ovario). FSHR tambi\u00e9n est\u00e1 acoplado a Gs, pero su programa descendente es distinto: en las c\u00e9lulas de Sertoli, la activaci\u00f3n de FSHR impulsa la prote\u00edna fijadora de andr\u00f3genos (ABP), la inhibina B y el programa de soporte estructural que sostiene la espermatog\u00e9nesis; en las c\u00e9lulas de la granulosa, la activaci\u00f3n de FSHR impulsa la CYP19A1 (aromatasa), convirtiendo los andr\u00f3genos derivados de las c\u00e9lulas de la teca en estr\u00f3genos, y promueve la maduraci\u00f3n folicular hasta las etapas antral y preovulatoria.<\/li>\n<li><strong>Modelo combinado de dos c\u00e9lulas y dos gonadotropinas<\/strong> \u2014 El marco endocrino cl\u00e1sico. En el test\u00edculo masculino, las c\u00e9lulas de Leydig estimuladas por LH producen testosterona, que difunde hacia las c\u00e9lulas de Sertoli adyacentes, donde la prote\u00edna fijadora de andr\u00f3genos inducida por FSH y la maquinaria metab\u00f3lica de las c\u00e9lulas de Sertoli la convierten en el microentorno de alta testosterona intratesticular que requiere la espermatog\u00e9nesis. En el ovario femenino, las c\u00e9lulas de la teca estimuladas por LH producen andr\u00f3genos, que difunden hacia las c\u00e9lulas de la granulosa adyacentes, donde la aromatasa inducida por FSH los convierte en estr\u00f3genos. El modelo de dos c\u00e9lulas y dos gonadotropinas es el marco can\u00f3nico, y el hMG es la herramienta farmacol\u00f3gica can\u00f3nica para activar ambas mitades simult\u00e1neamente.<\/li>\n<li><strong>Desensibilizaci\u00f3n del receptor y taquifilaxia<\/strong> \u2014 Both LHCGR and FSHR undergo arrestin-mediated desensitization after sustained agonist exposure. Repeated high-dose hMG dosing can produce receptor downregulation \u2014 a well-documented phenomenon in published gonadotropin-pharmacology studies relevant to chronic-dosing protocols.<\/li>\n<li><strong>Retroalimentaci\u00f3n hipot\u00e1lamo-hipofisaria<\/strong> \u2014 As with HCG, hMG-driven gonadal steroid output feeds back to the hypothalamus and pituitary to suppress endogenous GnRH and LH\/FSH secretion. In the context of HPG-suppression studies (testosterone replacement, AAS exposure, pharmacological GnRH antagonism), hMG bypasses the hypothalamic-pituitary blockade by acting directly at the gonadal receptors \u2014 preserving both Leydig-cell function (LH side) and Sertoli-cell \/ spermatogenesis-support function (FSH side) simultaneously, which is what distinguishes hMG from pure-HCG protocols in this context.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of hMG broadly mirrors that of its components: FSH activity persists with 30\u201340 h terminal half-life, LH-equivalent activity is dominated by the long-half-life co-purified HCG (33\u201337 h), and the combined preparation produces sustained 24\u201372 h dual gonadotropin stimulation per dose. Typical protocol dosing is 75\u2013225 IU SC daily in rodent or human-subject studies \u2014 equivalent to 1\u20133 vials of the 75 IU strength. <\/p>\n<h2>Published Evidence<\/h2>\n<p>hMG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacolog\u00eda de gonadotropinas \u2014 la referencia can\u00f3nica de doble receptor<\/strong> \u2014 most-cited dual LHCGR + FSHR agonist in published gonadotropin studies; standard reference compound for dissecting LH-only vs FSH-only vs combined gonadotropin signalling<\/li>\n<li><strong>Spermatogenesis induction studies<\/strong> \u2014 in hypogonadotropic-hypogonadism rodent models, hMG (with or without supplementary HCG) is the canonical tool for inducing spermatogenesis by restoring both Leydig-cell testosterone production and Sertoli-cell FSH support; standard protocol cycle is 75\u2013150 IU SC three times per week for 6\u201324 months in clinical-translational studies<\/li>\n<li><strong>Female ovarian-stimulation studies<\/strong> \u2014 the historical foundation tool of in-vitro fertilisation studies; hMG drives follicular development through the antral and pre-ovulatory stages in published ovulation-induction protocols, typically combined with HCG as ovulation trigger; widely used in studies on polycystic ovary syndrome (PCOS), unexplained infertility, and assisted reproductive technologies<\/li>\n<li><strong>Two-cell two-gonadotropin model studies<\/strong> \u2014 the canonical framework of gonadal steroidogenesis pharmacology; hMG is the standard tool for activating both halves of the model simultaneously; published Sertoli-Leydig co-culture and theca-granulosa co-culture uses hMG to recapitulate the physiological dual-receptor stimulus<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in published studies models where endogenous LH\/FSH has been suppressed (by exogenous testosterone, AAS exposure, or GnRH antagonism), hMG preserves both Leydig-cell function and Sertoli-cell function by direct gonadal receptor activation \u2014 distinguishing it from HCG-only protocols which preserve only LH-side function and risk Sertoli-cell atrophy<\/li>\n<li><strong>Farmacolog\u00eda comparativa frente a LH pura \/ FSH pura \/ HCG<\/strong> \u2014 las comparaciones publicadas cara a cara de hMG frente a LH recombinante (Luveris), FSH recombinante (Gonal-F \/ Puregon), HCG recombinante (Ovidrel) y varias combinaciones son extensas; la hMG es la referencia mixta 1:1 de origen urinario contra la cual se comparan todas estas<\/li>\n<li><strong>Desarrollo folicular y biolog\u00eda de las c\u00e9lulas de la granulosa<\/strong> \u2014 published ex-vivo follicular culture and primary granulosa-cell uses hMG to drive simultaneous theca-cell androgen production and granulosa-cell aromatase induction \u2014 the most physiologically relevant in-vitro stimulus available<\/li>\n<li><strong>Biolog\u00eda del cuerpo l\u00fateo<\/strong> \u2014 sustained LHCGR activation by the LH component (and co-purified HCG) maintains corpus-luteum function and progesterone production; used in studies on the luteal phase and luteo-placental transition<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/es\/hcg-peptide\/\">HCG (Gonadotropina Cori\u00f3nica Humana)<\/a> (agonista puro de LHCGR \u2014 comparaci\u00f3n directa; actividad solo en el lado de la LH), <a href=\"https:\/\/medsbase.com\/es\/kisspeptin-10\/\">Kisspeptina-10<\/a> (agonista de Kiss1R hipotal\u00e1mico \u2014 impulsa la pulsaci\u00f3n end\u00f3gena de GnRH), <a href=\"https:\/\/medsbase.com\/es\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin-receptor pharmacology \u2014 sexual-function studies), and <a href=\"https:\/\/medsbase.com\/es\/oxytocin-acetate\/\">Oxitocina Acetato<\/a> (hormona pept\u00eddica de la hip\u00f3fisis posterior). Explora el cat\u00e1logo completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks HMG (urinary-extracted menotropin) in a single lyophilized vial strength calibrated to the standard 1:1 LH:FSH bioactivity unit. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 UI de LH + 75 UI de FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength (the international-reference unit dose) \u2014 single-dose dual-gonadotropin stimulation, spermatogenesis-induction protocols (75\u2013225 IU SC three times per week), ovarian-stimulation studies, two-cell two-gonadotropin co-culture stimulation, comparative pharmacology vs recombinant pure-LH and pure-FSH preparations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 75:75 IU vial is the international-reference dose unit and the format used in essentially all published gonadotropin studies and clinical practice. Multiple-vial dosing (150 IU, 225 IU per administration) is standard for higher-dose protocols. The 30-vial pack is the more economical purchase per-IU for extended-cycle or multi-cohort protocols. <\/p>\n<h2>C\u00f3mo se compara \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/es\/hcg-peptide\/\">HCG<\/a> y hMG son las dos preparaciones de gonadotropinas derivadas de orina en este cat\u00e1logo, y act\u00faan sobre el sistema de receptores de gonadotropinas de formas mec\u00e1nicamente distintas. HCG es un <em>puro<\/em> agonista del receptor LH\/CG \u2014 activaci\u00f3n de c\u00e9lulas de Leydig\/c\u00e9lulas de la teca \u00fanicamente. La hMG es la <em>dual<\/em> LH + FSH preparation \u2014 engages both halves of the two-cell two-gonadotropin model simultaneously. The choice between them in studies depends on whether the protocol needs LH-side activation alone or combined LH-side + FSH-side activation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (Menotropina)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composici\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mezcla fija 1:1: LH 75 UI + FSH 75 UI por vial (+ trazas de HCG que dominan la se\u00f1al equivalente a LH in vivo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">HCG puro (extra\u00eddo de orina) \u2014 glicoprote\u00edna \u00fanica<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptores activados<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>y<\/em> FSHR \u2014 activaci\u00f3n dual del receptor de gonadotropina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR \u00fanicamente \u2014 receptor \u00fanico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fuente<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Orina posmenop\u00e1usica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Orina de mujeres embarazadas (uHCG) o c\u00e9lulas CHO recombinantes (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Spermatogenesis induction (preserves Sertoli-cell function), ovarian follicular stimulation, two-cell two-gonadotropin model studies, dual-receptor pharmacology<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leydig-cell-only stimulation, ovulation triggering (LH-surge mimic), Leydig-cell-specific HPG-suppression-recovery, LHCGR pharmacology<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h; actividad equivalente a LH dominada por HCG co-purificada (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (fase terminal)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 IU SC (1\u20133 viales) por administraci\u00f3n; 3\u00d7\/semana en protocolos cr\u00f3nicos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135,000 IU SC \/ IM (bolo \u00fanico); 250\u2013500 IU\/d\u00eda en protocolos cr\u00f3nicos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Unidad de dosificaci\u00f3n en vial<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 IU de bioactividad (la dosis unitaria de referencia internacional)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5,000 o 10,000 IU de bioactividad<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado en la AMA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Prohibido en todo momento en atletas masculinos (S2 \u2014 Hormonas pept\u00eddicas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Prohibido en todo momento en atletas masculinos (S2 \u2014 Hormonas pept\u00eddicas); exenci\u00f3n para atletas femeninas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on dual LHCGR + FSHR activation, spermatogenesis induction, or the canonical two-cell two-gonadotropin model, hMG is the standard reference compound. For studies focused on Leydig-cell-only stimulation, ovulation triggering, or HCG-specific LHCGR pharmacology, <a href=\"https:\/\/medsbase.com\/es\/hcg-peptide\/\">HCG<\/a> es la herramienta m\u00e1s espec\u00edfica. V\u00e9ase tambi\u00e9n <a href=\"https:\/\/medsbase.com\/es\/kisspeptin-10\/\">Kisspeptina-10<\/a> for upstream hypothalamic Kiss1R \/ GnRH-pulsatility studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 \u00bfNecesitas agua BAC?<\/strong> La reconstituci\u00f3n de cualquier vial liofilizado requiere agua bacteriost\u00e1tica est\u00e9ril. Combina este producto con nuestro <a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 vial multidosis de 30 mL, conservado con alcohol benc\u00edlico 0.9%, grado USP.<\/div>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en el embalaje original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo, congele los viales sin abrir a \u221220 \u00b0C (estable \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). El polvo liofilizado est\u00e1 estabilizado con manitol o lactosa y es razonablemente tolerante a la exposici\u00f3n breve a temperatura ambiente durante el manejo, pero debe devolverse a la refrigeraci\u00f3n de inmediato. Proteger de la luz. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> for each 75 IU vial, inject 1.0\u00a0mL of bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake) \u2014 this yields a working stock of 75 IU LH + 75 IU FSH per mL. For protocols that need higher concentrations (multi-vial pooling for higher single-dose), reconstitute 2\u20133 vials with the same 1.0\u00a0mL diluent total to give 150\u2013225 IU\/mL. <strong>Agite suavemente para disolver \u2014 no sacuda, no utilice v\u00f3rtex.<\/strong> La mezcla de alto cizallamiento disocia los heterod\u00edmeros \u03b1\/\u03b2 de los componentes de la LH y la FSH y destruye la bioactividad del gonadotropina-receptor. El liofilizado a base de manitol suele disolverse en 30-60 segundos con un suave movimiento circular. <strong>Normas cr\u00edticas de almacenamiento para el material reconstituido:<\/strong> una vez reconstituido, almacene a 2\u20138 \u00b0C y util\u00edcelo en un plazo de 30 d\u00edas. <strong>No congelar la hMG reconstituida<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers (the same physical-chemistry constraint as HCG) and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols requiring multiple aliquots, prepare aliquots at the time of reconstitution and store at 2\u20138 \u00b0C separately rather than freezing. <\/p>\n<h2>Preguntas frecuentes<\/h2>\n<h3>\u00bfCu\u00e1l es la diferencia entre la HMG y la HCG?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/es\/hcg-peptide\/\">HCG<\/a> is a pure LH\/CG-receptor agonist \u2014 single glycoprotein hormone (CAS 9002-61-3) that binds and activates only the LHCGR on Leydig \/ theca \/ granulosa \/ luteal cells. hMG is a 1:1 mixture of LH and FSH bioactivity \u2014 distinct glycoprotein hormones (combined CAS 61489-71-2) that bind both the LHCGR (LH side) and the FSHR (FSH side). The clinical and studies consequence is that hMG produces dual-receptor stimulation that engages both halves of the two-cell two-gonadotropin model (Leydig + Sertoli in males; theca + granulosa in females), where HCG produces single-receptor stimulation of the LHCGR side only. <\/p>\n<h3>What is the HCG co-purification in hMG, and why does it matter for studies?<\/h3>\n<p>Los an\u00e1lisis de composici\u00f3n publicados de preparaciones de hMG derivadas de orina informan que aproximadamente <strong>el 95% de la bioactividad mediada por el receptor de LH in vivo<\/strong> is actually attributable to trace HCG co-purified from postmenopausal urine, rather than to LH itself (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life vs LH&#8217;s ~20 min \u2014 so even small amounts of co-purified HCG dominate the cumulative in-vivo LH-equivalent signal. For protocols where this distinction matters (e.g., comparing pure-LH pharmacology vs HCG-contaminated mixed-LH signal), <strong>la LH recombinante (Luveris)<\/strong> es la herramienta m\u00e1s limpia. Para protocolos donde el objetivo es la activaci\u00f3n dual de LHCGR + FSHR en una proporci\u00f3n fija de 1:1, la hMG es la referencia can\u00f3nica. <\/p>\n<h3>\u00bfPor qu\u00e9 la hMG se obtiene de la orina de mujeres posmenop\u00e1usicas?<\/h3>\n<p>Las mujeres posmenop\u00e1usicas pierden la inhibici\u00f3n por retroalimentaci\u00f3n negativa ov\u00e1rica del eje hipot\u00e1lamo-hipofisario, lo que aumenta dr\u00e1sticamente la producci\u00f3n de LH y FSH hipofisarias \u2014 los niveles s\u00e9ricos t\u00edpicos de LH y FSH posmenop\u00e1usicas son de 50\u2013100+ mUI\/mL cada uno, un orden de magnitud superior a los valores premenop\u00e1usicos. Ambas hormonas se eliminan luego por v\u00eda renal en la orina en forma concentrada. Por lo tanto, la orina posmenop\u00e1usica agrupada es la fuente natural m\u00e1s concentrada de LH + FSH para la extracci\u00f3n a escala industrial. La industria de la hMG se construy\u00f3 sobre esta idea a principios de la d\u00e9cada de 1960 (Pergonal fue la preparaci\u00f3n original de Serono) y contin\u00faa hoy, aunque gran parte del mercado cl\u00ednico ha cambiado a preparaciones recombinantes de LH pura y FSH pura. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>Single-dose protocol use is typically 75\u2013225 IU SC per administration (1\u20133 vials of the 75 IU strength), with 3\u00d7\/week or daily dosing in chronic protocols. Spermatogenesis-induction protocols in published hypogonadotropic-hypogonadism studies typically use 75\u2013150 IU 3\u00d7\/week for 6\u201324 months in combination with HCG (the HCG provides additional Leydig-cell stimulation). In-vitro Sertoli-cell or granulosa-cell culture protocols typically use 1\u201310 IU\/mL in growth medium. Users should consult primary literature appropriate to the species, model, and endpoint. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre la hMG y la FSH recombinante pura (Gonal-F \/ Puregon)?<\/h3>\n<p>La FSH recombinante pura (follitropina alfa \/ Gonal-F; follitropina beta \/ Puregon; producida en c\u00e9lulas CHO a partir de ADNc clonados de las subunidades \u03b1 y \u03b2 de la FSH) contiene <em>solo<\/em> FSH bioactivity \u2014 no LH, no HCG. hMG contains both LH and FSH bioactivity at 1:1 ratio (plus trace HCG). For protocols that need pure FSHR activation isolated from LHCGR signalling, recombinant FSH is the correct tool. For protocols that need combined dual-receptor activation at physiological ratio, hMG is the correct tool. Published head-to-head trials in ovarian-stimulation have compared the two with broadly equivalent follicular-development endpoints but with subtly different oestradiol-response profiles (hMG tends to produce slightly higher mid-cycle oestradiol due to the LH-side androgen substrate it provides for granulosa-cell aromatase). <\/p>\n<h3>\u00bfPor qu\u00e9 no se puede congelar la hMG reconstituida?<\/h3>\n<p>Por la misma raz\u00f3n que la HCG \u2014 tanto la LH como la FSH son heterod\u00edmeros de dos subunidades asociadas no covalentemente (\u03b1 + \u03b2 cada una). La interacci\u00f3n \u03b1\/\u03b2 es estable en el liofilizado (no hay agua para alterar la interacci\u00f3n) y estable en soluci\u00f3n acuosa refrigerada a 2\u20138 \u00b0C (la cin\u00e9tica de disociaci\u00f3n es lenta a baja temperatura). Pero la formaci\u00f3n de cristales de hielo durante la congelaci\u00f3n separa f\u00edsicamente las subunidades, y estas se reasocian de manera ineficiente al descongelarse. El resultado es que la hMG congelada y descongelada retiene una gran fracci\u00f3n de inmunorreactividad pero pierde una gran fracci\u00f3n de actividad biol\u00f3gica. La hMG liofilizada se puede congelar y es estable a \u221220 \u00b0C; la hMG reconstituida no. <\/p>\n<h3>\u00bfCu\u00e1l es el estado regulatorio de la hMG seg\u00fan la WADA?<\/h3>\n<p>hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times \u2014 both in-competition and out-of-competition \u2014 for male athletes. Users conducting human-subject studies with hMG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>How does this pharmaceutical-grade hMG compare with the branded clinical preparations (Menopur, Menogon, Repronex)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted menotropin (Menopur, Menogon, Repronex; the historical Pergonal preparation has been largely discontinued) packaged under various manufacturer SKUs for clinical use in assisted reproductive technologies. The pharmaceutical-grade hMG supplied here is the same urinary-extracted preparation at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use menotropin should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <\/p>\n<h3>Can hMG be combined with HCG, Kisspeptin-10, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis and are commonly combined in published studies. The most-published combinations are hMG + HCG (the standard clinical and protocol for spermatogenesis induction in hypogonadotropic-hypogonadism models \u2014 hMG provides FSH-side support, additional HCG provides supplemental LH-side stimulation); hMG + <a href=\"https:\/\/medsbase.com\/es\/kisspeptin-10\/\">Kisspeptina-10<\/a> (upstream + downstream dissection \u2014 kisspeptin drives endogenous GnRH while hMG provides direct gonadal stimulation); hMG + exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses endogenous LH\/FSH and hMG bypasses the suppression by acting directly at the gonad). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 neither hMG nor HCG should be frozen reconstituted. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/hcg-peptide\/\"><strong>HCG (Gonadotropina Cori\u00f3nica Humana)<\/strong><\/a> \u2014 Agonista puro del receptor LH\/CG \u2014 comparaci\u00f3n directa; actividad solo en el lado de la LH<\/li>\n<li><a href=\"\/es\/kisspeptin-10\/\"><strong>Kisspeptina-10<\/strong><\/a> \u2014 Agonista de Kiss1R hipotal\u00e1mico \u2014 regulador ascendente del eje HPG, impulsa la pulsatilidad de GnRH<\/li>\n<li><a href=\"\/es\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/es\/oxytocin-acetate\/\"><strong>Oxitocina Acetato<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 An\u00e1logo de GHRH \u2014 eje endocrino diferente, com\u00fanmente coestudiado<\/li>\n<li><a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necesaria para reconstituir cualquier vial liofilizado \u2014 diluyente est\u00e9ril conservado con alcohol benc\u00edlico al 0.9%<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Preparaci\u00f3n dual de glicoprote\u00edna LH + FSH \u2014 relaci\u00f3n de bioactividad 1:1 (75 UI cada una)<br \/>\n\u2705 Agonista dual can\u00f3nico de los receptores LHCGR + FSHR<br \/>\n\u2705 Menotropina extra\u00edda de orina a partir de orina agrupada de mujeres posmenop\u00e1usicas (CAS 61489-71-2)<br \/>\n\u2705 Modelo de dos c\u00e9lulas y dos gonadotropinas: act\u00faa sobre c\u00e9lulas de Leydig+Sertoli o teca+granulosa<br \/>\n\u2705 Standard tool for spermatogenesis-induction &amp; ovarian-stimulation studies<\/p>\n<p><strong>HMG (Pharmaceutical Grade)<\/strong> contiene Menotropina Humana Menop\u00e1usica extra\u00edda de orina (menotropina).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":["post-71441","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hmg","product_tag-hpg-axis","product_tag-human-menopausal-gonadotropin","product_tag-lhcgr-fshr-agonist","product_tag-menotropin","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}